Bar, Jair <br/><br/>
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.  [electronic resource] 

 -  Clinical lung cancer  Nov 2015 
 - e189-201 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0690 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2015.05.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aldosterone--blood<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Pharmacological--blood<br/>Canada<br/>Carcinoma, Non-Small-Cell Lung--diagnosis<br/>Female<br/>Humans<br/>Lung Neoplasms--diagnosis<br/>Male<br/>Middle Aged<br/>Peptidyl-Dipeptidase A--blood<br/>Predictive Value of Tests<br/>Prognosis<br/>Quinazolines--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome